FrancophonIA/ELRC3.0 huggingface dataset:
English: During post-marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer hydrochloride.
Slovenian: Med izkušnjami v obdobju trženja so poročali o zelo redkih primerih zvišanih ravni fosforja pri bolnikih, ki so sočasno jemali sevelamerijev klorid in zaviralce protonske črpalke.
English: Patients should take sevelamer hydrochloride with meals and adhere to their prescribed diets.
Slovenian: Bolniki morajo jemati sevelamerijev klorid ob obroku in se držati predpisanih diet. Tablete je treba pogoltniti cele.
English: If you do not take multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in your blood and therefore your doctor may monitor these levels and prescribe supplemental
Slovenian: Zato utegne vaš zdravnik nadzirati koncentracijo vitamina D v krvi in vam po potrebi predpisati dodatek vitamina D. Če ne jemljete multivitaminskih dodatkov, vam lahko pade tudi koncentracija vitaminov A, E, K in folne kisline v krvi, zato utegne vaš zdravnik nadzirati tudi te koncentracije in vam po potrebi predpisati dodatne vitamine.
English: Each tablet contains 800 mg sevelamer hydrochloride.
Slovenian: Ena tableta zdravila Tasermity vsebuje 800 mg sevelamerijevega klorida.
English: Tasermity is used to control the levels of phosphate in the blood of adult kidney failure patients on haemodialysis or peritoneal dialysis treatment.
Slovenian: Zdravilo Tasermity se uporablja za uravnavanje koncentracije fosfatov v krvi pri odraslih bolnikih s kronično ledvično odpovedjo, ki se zdravijo s hemodializo oziroma peritonealno dializo.
English: The effects on phosphate and calcium were proven to be maintained throughout a study with one year follow-up.
Slovenian: V enoletni raziskavi so dokazali, da se učinki na fosfat in kalcij ohranijo.
English: Therefore your doctor may monitor the levels of TSH in your blood more closely.
Slovenian: Zato se lahko vaš zdravnik odloči za skrbno nadziranje
English: Renal impairment The safety and efficacy of this product have not been established in predialysis patients.
Slovenian: Varnosti in učinkovitosti tega zdravila pri bolnikih z ledvično okvaro, ki niso na dializi, niso ugotavljali.
English: Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Slovenian: Sevelamerijev klorid je treba uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog, za nadziranje razvoja renalne osteodistrofije.
English: Fat-soluble vitamins
Slovenian: V maščobi topni vitamini
English: The safety of sevelamer hydrochloride has not been established in breast-feeding women.
Slovenian: Varnosti sevelamerijevega klorida pri doječih ženskah niso ugotavljali.
English: Check with your doctor if you are not sure.
Slovenian: Če niste prepričati, se posvetujte z zdravnikom.
English: Depending on diet intake and the nature of end stage renal failure, dialysis patients may develop low vitamin A, D, E and K levels.
Slovenian: Glede na vnos hrane in naravo končne odpovedi ledvic se lahko pri dializnih bolnikih pojavijo nizke ravni vitaminov A, D, E in K. Ni mogoče izključiti, da lahko sevelamerijev klorid veže v maščobi topne vitamine v zaužiti hrani.
English: Tasermity may be used with other medicines which include calcium or vitamin D supplements to control the development of renal bone disease.
Slovenian: Zdravilo Tasermity se lahko uporablja sočasno s terapijo preprečevanja razvoja bolezni kosti, v sklopu katere se dodaja kalcij in vitamin D.
English: Gastrointestinal disorders
Slovenian: Zaviralci protonske črpalke
English: He/she will base the dose on your serum phosphate level.
Slovenian: Zdravnik bo odmerek določil glede na koncentracijo fosfata v serumu.
English: How to store Tasermity
Slovenian: Shranjevanje zdravila Tasermity
English: Uncommon reports of difficulty swallowing the sevelamer hydrochloride tablet have been reported.
Slovenian: Občasno so poročali o težavah s požiranjem tablet s sevelamerijevim kloridom.
English: Common (may affect up to 1 in 10 people): diarrhoea, indigestion, abdominal pain, constipation, flatulence.
Slovenian: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): driska, slaba prebava, bolečine v trebuhu, zaprtost, nabiranje plinov v želodcu in črevesju Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): povečana kislost krvi
English: - The active substance is sevelamer hydrochloride.
Slovenian: - Zdravilna učinkovina je sevelamerijev klorid.
English: Therefore caution should be exercised when sevelamer hydrochloride is used in patients with these disorders.
Slovenian: Zato je treba biti pri teh bolnikih z uporabo sevelamerijevega klorida zelo pazljiv.
English: • if you have bowel obstruction.
Slovenian: • če imate zaporo črevesja,
English: Acidosis, increased chloride
Slovenian: Presnovne in prehranske motnje acidoza, zvišana vrednost klorida v serumu
English: Sevelamer hydrochloride treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
Slovenian: Pri bolnikih, ki imajo hudo zaprtje ali druge hude gastrointestinalne simptome, je treba ponovno pretehtati smiselnost zdravljenja s sevelamerijevim kloridom.
English: Posology
Slovenian: Levotiroksin
English: • if you have problems with motility (movement) in your stomach and bowel
Slovenian: • imate težave z nenormalno ali nepravilno gibljivostjo želodca in črevesja
English: Nederland sanofi-aventis Netherlands B.V. Tel: +31 182 557 755
Slovenian: Κύπρος sanofi-aventis Cyprus Ltd. Τηλ: +357 22 871600
English: Sevelamer hydrochloride is not absorbed from the gastrointestinal tract according to a single dose pharmacokinetic study in healthy volunteers.
Slovenian: Glede na farmakokinetične raziskave zdravih prostovoljcev z enim samim odmerkom se sevelamerijev klorid ne absorbira iz gastrointestinalnega trakta.
English: • Bowel obstruction.
Slovenian: Okvara ledvic
English: Τηλ: +357 22 871600
Slovenian: Tel: +31 182 557 755
English: Sevelamer hydrochloride treatment should be re-evaluated in patients who develop severe gastrointestinal symptoms.
Slovenian: Pri bolnikih, ki se jim pojavijo hudi simptomi povezani s prebavili, je treba zdravljenje s sevelamerijevim kloridom znova oceniti.
English: 49 x 1 tablets (unit dose)
Slovenian: 196 (2 x 98) tablet
English: l t o r
Slovenian: Pot uporabe
English: Target Species
Slovenian: Ciljna živalska
English: Packaging
Slovenian: Farmacevtska
English: EU Number
Slovenian: EU številka Izmišljeno ime Jakost
English: Package size
Slovenian: Ovojnina Velikost pakiranja Karenca
English: London, 19 July 2007 Doc.
Slovenian: London, 19. julij 2007 Sklic na dok.
English: The Committee also had concerns over the ways in which the study had been carried out, which made it difficult to interpret the results.
Slovenian: Odbor je imel tudi pomisleke v zvezi z načinom izvedbe študije, zaradi česar je bilo rezultate težko interpretirati.
English: The letter from the company notifying the EMEA of the withdrawal of the application is available here.
Slovenian: Dopis podjetja, v katerem je agencijo EMEA obvestilo o umiku vloge, je na voljo tukaj.
English: The main measure of effectiveness was how long the patients survived after the first operation.
Slovenian: Glavno merilo učinkovitosti je bil čas preživetja bolnikov po prvi operaciji.
English: Ref. EMA/318692/2007
Slovenian: EMA/382244/2007
English: Cerepro was designated an orphan medicinal product on 6 February 2002.
Slovenian: Zdravilo Cerepro je bilo dne 6. februarja 2002 določeno kot zdravilo sirota.
English: The company had requested a re-examination of the negative opinion, but this had not yet finished when the company withdrew.
Slovenian: Podjetje je zahtevalo ponovno preučitev negativnega mnenja, ki pa še ni bila zaključena, ko se je podjetje odločilo za umik svoje vloge.
English: The effects of Cerepro were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Cerepro so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for CEREPRO
Slovenian: VPRAŠANJA IN ODGOVORI GLEDE UMIKA VLOGE ZA DOVOLJENJE ZA PROMET za zdravilo CEREPRO
English: It was concerned over the low number of patients included in the main study of Cerepro, which prevented a benefit of the medicine being demonstrated.
Slovenian: Zaskrbljen je bil glede majhnega števila bolnikov, vključenih v glavno študijo zdravila Cerepro, zaradi česar koristi zdravila ni bilo mogoče dokazati.
English: What are the consequences of the withdrawal for patients in clinical trials with Cerepro?
Slovenian: Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih zdravila Cerepro?
English: Cerepro has also been studied in 36 patients with high-grade glioma.
Slovenian: Zdravilo Cerepro so preučevali tudi pri 36 bolnikih z visoko malignimi gliomi.
English: The study compared the effects of adding Cerepro and ganciclovir sodium to standard treatment with the effects of standard treatment alone.
Slovenian: V okviru študije so primerjali učinek dodajanja zdravila Cerepro in ganciklovir natrija k standardnemu zdravljenju z učinkom standardnega zdravljenja samega.
English: Cerepro injection was to be followed by a two-week course of treatment with ganciclovir sodium, starting five days after the operation.
Slovenian: Injiciranju zdravila Cerepro bi naj sledilo dvotedensko zdravljenje z ganciklovir natrijem, ki bi se pričelo pet dni po operaciji.
English: On 13 July 2007, Ark Therapeutics officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Cerepro, for the treatment of patients with operable high-grade glioma.
Slovenian: Podjetje Ark Therapeutics je dne 13. julija 2007 obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti svojo vlogo za izdajo dovoljenja za promet z zdravilom Cerepro, namenjenim zdravljenju bolnikov z operabilnimi visoko malignimi gliomi.
English: After removing as much of the brain tumour as possible, the surgeon would have made up to 70 small injections of Cerepro into the area from where the tumour was removed.
Slovenian: Po odstranitvi čim večjega dela možganskega tumorja bi naj kirurg v področje, iz katerega je bil tumor odstranjen, vbrizgal do 70 majhnih injekcij zdravila Cerepro.
English: This enzyme helps to convert ganciclovir into a form which can kill cells that are dividing, including any cancerous cells that were not removed during the operation.
Slovenian: Ta encim sodeluje pri pretvorbi ganciklovira v obliko, ki lahko ubije celice, ki se razmnožujejo, kot so na primer rakave celice, ki niso bile odstranjene med operacijo.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend a marketing authorisation for Cerepro for the treatment of patients with operable high-grade glioma.
Slovenian: Na podlagi pregleda podatkov in odgovorov podjetja na seznam vprašanj CHMP je v času umika vloge CHMP izrazil negativno mnenje in ni priporočil odobritve dovoljenja za promet za zdravilo Cerepro, namenjeno zdravljenju bolnikov z operabilnimi visoko malignimi gliomi.
English: Glioma is a type of brain tumour that begins in ‘glial' cells (the cells that surround and support nerve cells).
Slovenian: Gliom je vrsta možganskega tumorja, ki se prične v nevroglijski celici (celici, ki obkroža in podpira živčno celico).
English: In addition, the CHMP considered there to be insufficient information on the safety of Cerepro, and, since the benefits of the medicine had not been demonstrated, that its risks, when used in combination with ganciclovir, could be of concern.
Slovenian: Poleg tega je CHMP menil, da ni dovolj informacij o varnosti zdravila Cerepro ter da utegnejo biti glede na dejstvo, da korist zdravila ni bila dokazana, njegova tveganja ob uporabi v kombinaciji z ganciklovirjem zaskrbljujoča.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Cerepro.
Slovenian: Podjetje je CHMP obvestilo, da ni posledic za bolnike, ki trenutno sodelujejo v kliničnih preizkušanjih zdravila Cerepro.
English: The gene is carried within a ‘vector', a type of virus that has been altered genetically so that it can carry a gene (DNA) into the cells of the body.
Slovenian: Gen se prenaša s pomočjo „vektorja“, vrste virusa, ki je bila genetsko spremenjena tako, da lahko prenaša gen (DNA) v celice telesa.
English: Cerepro would only have worked in combination with ganciclovir.
Slovenian: Zdravilo Cerepro bi delovalo izključno v kombinaciji z ganciklovirjem.
English: What is Cerepro?
Slovenian: Kaj je zdravilo Cerepro?
English: Cerepro was intended for use during an operation.
Slovenian: Zdravilo Cerepro bi se naj uporabljalo med operacijo.
English: The virus in Cerepro is an ‘adenovirus' that has been engineered so that it cannot make copies of itself and therefore does not cause infections in humans.
Slovenian: Virus, uporabljen pri zdravilu Cerepro, je „adenovirus“, ki je bil gensko spremenjen tako, da se ne more podvojevati in posledično v ljudeh ne more povzročiti okužbe.
English: The CHMP had concerns that a benefit of Cerepro had not yet been shown.
Slovenian: CHMP je izrazil zadržek, da korist zdravila Cerepro še ni bila dokazana.
English: Cerepro was to be used in combination with ganciclovir sodium to treat high-grade glioma in patients who are eligible for surgery.
Slovenian: Zdravilo Cerepro bi se naj v kombinaciji z ganciklovir natrijem uporabljalo za zdravljenje visoko malignih gliomov pri bolnikih, primernih za operacijo.
English: What was Cerepro expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Cerepro uporabljalo?
English: It is made up into a solution that is injected directly into the brain during surgery.
Slovenian: Zdravilo se pripravi v obliki raztopine, ki se med operacijo injicira neposredno v možgane.
English: When Cerepro is injected into the brain, the modified virus is taken up by the cells near the injection sites.
Slovenian: Ko se zdravilo Cerepro injicira v možgane, celice v bližini mesta injiciranja privzamejo spremenjeni virus.
English: How is Cerepro expected to work?
Slovenian: Kako naj bi zdravilo Cerepro delovalo?
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Cerepro had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Slovenian: CHMP je zato v času umika menil, da koristi zdravila Cerepro niso bile zadostno dokazane in da ne odtehtajo znanih tveganj.
English: Cerepro is a medicine containing a gene (a Herpes simplex virus thymidine kinase gene) carried by an adenovirus.
Slovenian: Cerepro je zdravilo, ki vsebuje gen (gen za timidin kinazo virusa Herpes simplex), ki ga nosi adenovirus.
English: The cells then start to produce the thymidine kinase enzyme.
Slovenian: Celice pričnejo tvoriti encim timidin kinazo.
English: Cerepro contains the gene for the enzyme ‘thymidine kinase' from the herpes virus.
Slovenian: Zdravilo Cerepro vsebuje gen za encim „timidin kinazo“ iz virusa herpesa.
English: Active substance: adenovirus-mediated Herpes simplex virus-thymidine kinase gene
Slovenian: Zdravilna učinkovina: gen za timidin kinazo virusa Herpes simplex, posredovan z adenovirusom
English: Further information on Nivestim can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/nivestim.
Slovenian: Nadaljnje informacije o zdravilu Nivestim so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/nivestim.
English: Nivestim received a marketing authorisation valid throughout the EU on 8 June 2010.
Slovenian: Za zdravilo Nivestim je bilo 8. junija 2010 izdano dovoljenje za promet, veljavno po vsej EU.
English: This means that Nivestim is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Slovenian: To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
English: What measures are being taken to ensure the safe and effective use of Nivestim?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Nivestim?
English: An overview of Nivestim and why it is authorised in the EU
Slovenian: Pregled zdravila Nivestim in zakaj je odobreno v EU
English: What is Nivestim and what is it used for?
Slovenian: Kaj je zdravilo Nivestim in za kaj se uporablja?
English: What benefits of Nivestim have been shown in studies?
Slovenian: Kakšne koristi zdravila Nivestim so se pokazale v študijah?
English: What are the risks associated with Nivestim?
Slovenian: Kakšna tveganja so povezana z zdravilom Nivestim?
English: The active substance in Nivestim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Slovenian: Učinkovina zdravila Nivestim, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije spodbujajoči faktor (G-CSF).
English: Filgrastim works in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.
Slovenian: Filgrastim deluje enako kot naravno tvorjeni G-CSF, kar pomeni, da spodbuja kostni mozeg k tvorjenju večjega števila belih krvnih celic.
English: As for all medicines, data on the use of Nivestim are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Nivestim stalno spremljajo.
English: In addition, a study in 279 female adult patients with breast cancer who were being treated with cancer medicines showed that Nivestim is comparable to the reference medicine, Neupogen.
Slovenian: Poleg tega je študija pri 279 odraslih bolnicah z rakom dojke, ki so se zdravile z zdravili za zdravljenje raka, pokazala, da je zdravilo Nivestim primerljivo z referenčnim zdravilom Neupogen.
English: Nivestim can only be obtained with a prescription and treatment should be given in collaboration with a centre for cancer treatment.
Slovenian: Predpisovanje in izdaja zdravila Nivestim je le na recept, zdravljenje pa se lahko uvede v sodelovanju z centrom za zdravljenje raka.
English: Other side effects may be seen in more than 1 in 10 patients, depending on the condition that Nivestim is being used for.
Slovenian: Drugi neželeni učinki se lahko pojavijo pri več kot 1 od 10 bolnikov, odvisno od bolezni, ki se zdravi z zdravilom Nivestim.
English: For more information about using Nivestim, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Nivestim glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The way Nivestim is given, its dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment.
Slovenian: Način dajanja in odmerjanje zdravila Nivestim ter trajanje zdravljenja z njim so odvisni od razloga za uporabo zdravila, telesne mase bolnika in odziva na zdravljenje.
English: The medicine is available in pre-filled syringes and is given by injection under the skin or infusion (drip) into a vein.
Slovenian: Zdravilo je na voljo v obliki napolnjenih injekcijskih brizg in se daje z injiciranjem v podkožje ali infundiranjem (kapalno infuzijo) v veno.
English: Nivestim can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Slovenian: Zdravilo Nivestim lahko uporabljajo tudi darovalci krvnih matičnih celic, namenjenih za presaditev, da se olajša sproščanje teh celic iz kostnega mozga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nivestim have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Nivestim upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Side effects reported with Nivestim are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Nivestim, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: The most common side effects with Nivestim (which may affect more than 1 in 10 people) are fever, musculoskeletal pain (pain in the muscles and bones), anaemia (low red blood cell counts), vomiting and nausea (feeling sick).
Slovenian: Najpogostejši neželeni učinki zdravila Nivestim (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so povišana telesna temperatura, mišično-skeletne bolečine (bolečine v mišicah in kosteh), anemija (nizko število rdečih krvnih celic), bruhanje in navzeja (slabost).
English: Why is Nivestim approved?
Slovenian: Zakaj je bilo zdravilo Nivestim odobreno?
English: • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
Slovenian: • za povišanje ravni nevtrofilcev in zmanjšanje tveganja okužb pri bolnikih z nevtropenijo, ki imajo anamnezo hudih, ponavljajočih se okužb;
English: The patients who received Nivestim had severe neutropenia for a similar length of time as the patients who received Neupogen.
Slovenian: Pri bolnikih, ki so prejemali zdravilo Nivestim, je huda nevtropenija trajala podobno dolgo kot pri bolnikih, ki so prejemali zdravilo Neupogen.
English: The safety of Nivestim has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neupogen.
Slovenian: Varnost zdravila Nivestim je bila ocenjena in na podlagi vseh izvedenih študij so bili neželeni učinki zdravila ocenjeni kot primerljivi z neželenimi učinki referenčnega zdravila Neupogen.
English: All these data were considered sufficient to conclude that Nivestim will behave in the same way as Neupogen in terms of effectiveness and safety in its authorised uses.
Slovenian: Vsi ti podatki so bili ocenjeni kot zadostni za zaključek, da se bo zdravilo Nivestim pri odobrenih uporabah z vidika učinkovitosti in varnosti vedlo enako kot zdravilo Neupogen.
English: Other information about Nivestim
Slovenian: Druge informacije o zdravilu Nivestim
English: • to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and to prevent febrile neutropenia (neutropenia with fever) in cancer patients (excluding patients with chronic myeloid leukaemia or with myelodysplastic syndromes).
Slovenian: • za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvnih celic) in preprečevanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih z rakom (razen pri bolnikih s kronično mieloično levkemijo ali mielodisplastičnimi sindromi).
English: Therefore, the Agency's view was that, as for Neupogen, the benefits of Nivestim are greater than its risks and it can be authorised or use in the EU.
Slovenian: Menila je, da so koristi zdravila Nivestim, enako kot pri zdravilu Neupogen, večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Nivestim has a highly similar structure, purity and biological activity to Neupogen and is distributed in the body in the same way.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Nivestim po zgradbi, čistosti in biološkem delovanju primerljivo zdravilu Neupogen in da se po telesu enako prenaša.